Department of Clinical Pharmacy & Pharmacy Administration, West China Pharmacy School, Sichuan University, No. 17 Section 3 Renmin Nanlu, Chengdu, Sichuan 610041, China.
Evid Based Complement Alternat Med. 2013;2013:791724. doi: 10.1155/2013/791724. Epub 2013 May 13.
Context. Modified Chaihu Shugan powder (MCSP) is a popular traditional Chinese herbal formula for functional dyspepsia, which is revised from Chaihu Shugan San and recorded in a medical classic works of China. However, its role and effect in treating functional dyspepsia have not been well established. Objective. To assess the effect and safety of modified Chaihu Shugan powder for functional dyspepsia. Methods. We searched the published and unpublished studies up to August 2012. Only RCTs of modified Chaihu Shugan powder with or without prokinetic drugs versus prokinetic drugs in the patients diagnosed with functional dyspepsia were included. Results. Twenty-two clinical trials involving 1998 participants were included. There were evidences that modified Chaihu Shugan powder (RR = 1.20, 95%, CI 1.14 to 1.27) and modified Chaihu Shugan powder plus prokinetic drugs (RR = 1.18, 95%, CI 1.11 to 1.25) were significantly better treatment options than prokinetic drugs alone in improving symptoms. No serious adverse events were described in the included trials. Conclusions. This meta-analysis showed that modified Chaihu Shugan powder alone or in combination with prokinetic drugs might be more effective than prokinetic drugs alone. However, with poor methodological quality, all the included trials were at high risk of bias. Further large-scale high-quality trials are required for assessment.
加味柴胡疏肝散（MCSP）是一种常用于治疗功能性消化不良的中药方剂，由柴胡疏肝散加减而成，收载于中国的一部医学经典著作中。然而，其治疗功能性消化不良的疗效和安全性尚未得到充分证实。目的：评估加味柴胡疏肝散治疗功能性消化不良的疗效和安全性。方法：我们检索了截至 2012 年 8 月发表和未发表的研究。仅纳入加味柴胡疏肝散与或不与促动力药联合治疗功能性消化不良患者的随机对照试验。结果：纳入了 22 项临床试验，共 1998 名参与者。有证据表明，加味柴胡疏肝散（RR=1.20，95%CI 1.14 至 1.27）和加味柴胡疏肝散联合促动力药（RR=1.18，95%CI 1.11 至 1.25）在改善症状方面明显优于单纯使用促动力药。纳入的试验中均未描述严重不良事件。结论：本荟萃分析显示，加味柴胡疏肝散单独使用或联合促动力药可能比单纯使用促动力药更有效。然而，由于方法学质量较差，所有纳入的试验均存在高度偏倚风险。需要进一步开展大规模高质量的试验来进行评估。
